What service do you need? Contact Request

NCT06149559

A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis

← Clinical trials hub

Registry fields

Overall status: ACTIVE_NOT_RECRUITING
Conditions: Generalized Myasthenia Gravis
Study type: INTERVENTIONAL
Phase: PHASE2, PHASE3
Primary purpose: TREATMENT
Intervention type: DRUG
Interventions: rozanolixizumab
Lead sponsor: UCB Biopharma SRL (INDUSTRY)

Cached at: 2026-09-26 09:28:20

View on ClinicalTrials.gov

Brief summary

The purpose of the study is to assess the safety and tolerability of subcutaneous (sc) administration of rozanolixizumab in pediatric participants aged ≥2 to \<18 years with generalized Myasthenia Gravis (gMG).

Contact

Need a report or Korean medical writing based on this trial?

Request a report Medical writing Custom research report

Contact Support